Should I buy or sell Amarin stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" AMRN shares. View AMRN analyst ratings or view top-rated stocks .

What is Amarin's stock price target for 2024?

4 equities research analysts have issued 12-month price objectives for Amarin's stock. Their AMRN share price targets range from $1.00 to $1.25. On average, they predict the company's share price to reach $1.08 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts .

How have AMRN shares performed in 2024?

Amarin's stock was trading at $0.87 at the beginning of 2024. Since then, AMRN stock has increased by 2.6% and is now trading at $0.8925. View the best growth stocks for 2024 here .

When is Amarin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our AMRN earnings forecast .

How can I listen to Amarin's earnings call?

Amarin will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "50260".

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) released its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.04. The biopharmaceutical company had revenue of $74.71 million for the quarter, compared to the consensus estimate of $72.46 million. Amarin had a negative trailing twelve-month return on equity of 10.47% and a negative net margin of 19.26%.

What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com . John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU) , Advanced Micro Devices (AMD) , NVIDIA (NVDA) , Block (SQ) , Alibaba Group (BABA) , Tesla (TSLA) , Bank of America (BAC) , Netflix (NFLX) and Novavax (NVAX) .

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Amarin have any subsidiaries?

The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited. Read More

NASDAQ:AMRN

Amarin (AMRN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AMRN Stock Alerts

$0.89

-0.02 (-2.68%)

(As of 12:34 PM ET)

Compare

Today's Range: $0.88
▼
$0.96
50-Day Range: $0.82
▼
$1.35
52-Week Range: $0.65
▼
$1.49

Volume: 445,943 shs
Average Volume: 2.04 million shs
Market Capitalization: $366.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.08

Get Amarin alerts:

Amarin MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.75 Rating Score
Upside/Downside: 21.4% Upside
$1.08 Price Target
Short Interest: Healthy
4.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$15,724 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.14) to ($0.20) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.40 out of 5 stars

Medical Sector

878th out of 914 stocks

Pharmaceutical Preparations Industry

402nd out of 418 stocks

1.9

Analyst's Opinion

Consensus Rating
Amarin has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 1 hold rating, and 2 sell ratings.
Amount of Analyst Coverage
Amarin has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.39% of the outstanding shares of Amarin have been sold short.
Short Interest Ratio / Days to Cover
Amarin has a short interest ratio ("days to cover") of 8.2.
Change versus previous month
Short interest in Amarin has recently decreased by 0.93%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Amarin does not currently pay a dividend.
Dividend Growth
Amarin does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMRN.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for Amarin this week, compared to 2 articles on an average week.
Search Interest
Only 10 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amarin insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,724.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.96% of the stock of Amarin is held by insiders.
Percentage Held by Institutions
Only 22.25% of the stock of Amarin is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Amarin are expected to decrease in the coming year, from ($0.14) to ($0.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amarin is -6.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amarin is -6.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Amarin has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Amarin Stock (NASDAQ:AMRN)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AMRN Stock News Headlines

April 18, 2024 | seekingalpha.com

Amarin Corporation: Small Signs Of Recovery May Not Be Enough

April 16, 2024 | americanbankingnews.com

Amarin (NASDAQ:AMRN) Stock Price Passes Above Two Hundred Day Moving Average of $0.93

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 15, 2024 | globenewswire.com

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

April 8, 2024 | finanznachrichten.de

Amarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

April 8, 2024 | globenewswire.com

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

April 6, 2024 | globenewswire.com

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

April 3, 2024 | fool.com

Why Amarin Stock Was Rocketing Higher on Wednesday

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 3, 2024 | markets.businessinsider.com

Amarin: IP Protection For VAZKEPA In Europe Now Extended Into 2039 - Quick Facts

April 3, 2024 | globenewswire.com

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

March 25, 2024 | finance.yahoo.com

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

March 25, 2024 | globenewswire.com

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

March 16, 2024 | finance.yahoo.com

AMRN Apr 2024 3.000 call

March 8, 2024 | finance.yahoo.com

AMRN Apr 2024 1.500 put

March 7, 2024 | finance.yahoo.com

AMRN May 2024 1.000 call

March 6, 2024 | finance.yahoo.com

AMRN Mar 2024 0.500 call

March 5, 2024 | finance.yahoo.com

Amarin Full Year 2023 Earnings: Beats Expectations

March 2, 2024 | seekingalpha.com

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

Earnings Update: Amarin Corporation plc (NASDAQ:AMRN) Just Reported And Analysts Are Trimming Their Forecasts

March 1, 2024 | finance.yahoo.com

Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript

February 29, 2024 | markets.businessinsider.com

Amarin’s Sell Rating Affirmed Amid Declining U.S. Sales and Uncertain International Expansion

February 29, 2024 | fool.com

Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript

February 29, 2024 | msn.com

Why Is Amarin Stock Trading Lower After Q4 Earnings?

February 29, 2024 | finanznachrichten.de

Amarin Corporation plc: Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 29, 2024 | msn.com

Amarin Non-GAAP EPS of $0.00 beats by $0.03, revenue of $74.71M beats by $3.61M

February 29, 2024 | finance.yahoo.com

Amarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic Competition

See More Headlines

Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AMRN
CUSIP: N/A
CIK: 897448
Web: www.amarincorp.com
Phone: (531) 669-9020
Fax: N/A
Employees: 275
Year Founded: 1991

Price Target and Rating

Average Stock Price Target: $1.08
High Stock Price Target: $1.25
Low Stock Price Target: $1.00
Potential Upside/Downside: +18.1%
Consensus Rating: Reduce
Rating Score (0-4): 1.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,110,000.00
Net Margins: -19.26%
Pretax Margin: -17.49%
Return on Equity: -10.47%
Return on Assets: -6.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.80
Quick Ratio: 1.80

Sales & Book Value

Annual Sales: $306.91 million
Price / Sales: 1.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.35 per share
Price / Book: 0.68

Miscellaneous

Outstanding Shares: 410,670,000
Free Float: 402,623,000
Market Cap: $376.63 million
Optionable: Optionable
Beta: 1.98

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Patrick J. Holt (Age 51)
President, CEO & Director
Comp: $678.88k
Mr. Thomas Charles Reilly (Age 51)
Executive VP, CFO & Global Head of HR
Comp: $1.01M
Dr. Steven B. Ketchum Ph.D. (Age 59)
Executive VP, President of Research & Development and Chief Scientific Officer
Comp: $1.16M
Mr. Jonathan N. Provoost (Age 54)
Executive VP, Chief Legal & Compliance Officer and Secretary
Comp: $160.08k
Mr. Aaron D. Berg (Age 61)
Executive VP & President of U.S.
Comp: $1.26M
Mr. Jordan Zwick (Age 37)
Senior VP of Corporate Business Development & Investor Relations
Mr. Laurent Abuaf
President of Europe & Senior VP
Dr. Nabil Abadir
Chief Medical Officer of Global Medical Affairs
Dr. David Keenan Ph.D.
Executive VP of Technical Operations & President of Europe

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amarin stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" AMRN shares.
View AMRN analyst ratings or view top-rated stocks.
What is Amarin's stock price target for 2024?: 4 equities research analysts have issued 12-month price objectives for Amarin's stock. Their AMRN share price targets range from $1.00 to $1.25. On average, they predict the company's share price to reach $1.08 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price.
View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts.
How have AMRN shares performed in 2024?: Amarin's stock was trading at $0.87 at the beginning of 2024. Since then, AMRN stock has increased by 2.6% and is now trading at $0.8925.
View the best growth stocks for 2024 here.
When is Amarin's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our AMRN earnings forecast.
How can I listen to Amarin's earnings call?: Amarin will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "50260".
How were Amarin's earnings last quarter?: Amarin Co. plc (NASDAQ:AMRN) released its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.04. The biopharmaceutical company had revenue of $74.71 million for the quarter, compared to the consensus estimate of $72.46 million. Amarin had a negative trailing twelve-month return on equity of 10.47% and a negative net margin of 19.26%.

What is John Thero's approval rating as Amarin's CEO?: 43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.
What other stocks do shareholders of Amarin own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).
How do I buy shares of Amarin?: Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Amarin have any subsidiaries?: The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More

This page (NASDAQ:AMRN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amarin (AMRN) Stock Price, News & Analysis

Amarin MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Amarin Stock (NASDAQ:AMRN)

AMRN Stock Price History

AMRN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

AMRN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™